Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 2/20 | 0.73 |
| ▸ | DGKG | P49619 | 1/20 | 0.73 |
| ▸ | DGKB | Q9Y6T7 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14473840 | 0.89 | DGKA (0.69) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL14177937 | 0.87 | DGKA (0.67) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL13294852 | 0.85 | KDM4E (0.72) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL13294520 | 0.84 | DGKA (0.66) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL23609422 | 0.83 | DGKA (0.61) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL13294983 | 0.83 | KDM4E (0.64) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL3152870 | 0.82 | DGKA (0.57) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL13294872 | 0.81 | DGKA (0.59) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL13294850 | 0.81 | DGKA (0.56) | DGKADGKGDGKBMAPTNPSR1 | |
| SCHEMBL13294964 | 0.80 | DGKA (0.58) | DGKADGKGDGKBMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732146-B2 | Method for screening an agent that modulates activity of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2010-06-08 | — | — | US | disclosed |
| US-7514225-B2 | Method for screening an agent that modulates activity of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7435737-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTIALS (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070197547-A1 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | AVANIR PHARMACEUTICALS (US) | 2007-08-23 | — | — | US | disclosed |
| US-7235565-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-06-26 | — | — | US | disclosed |
| US-7230106-B2 | Process for the preparation of inhibitors of macrophage migration inhibitory factor | AVANIR PHARMACEUTICALS (US) | 2007-06-12 | — | — | US | disclosed |
| US-7202248-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-04-10 | — | — | US | disclosed |
| US-7192955-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-01-25 | — | — | US | disclosed |
| US-7157469-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | DGKA 4626/4885DGKG 4367/4885DGKB 4004/4885 |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | DGKA 2199/4885DGKG 2529/4885DGKB 2000/4885 |
| US-20070197547-A1 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | MIF, MSR1, MMP12 | DGKA 4626/4885DGKG 4367/4885DGKB 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.